Khosla Ventures led a $40m Series A round in Vivodyne.

Khosla Ventures, a venture capital firm, led a $40m Series A round in Vivodyne, a biopharmaceutical company, with participation from Lingotto Investment Management, Helena Capital, Fortius Ventures, Kairos Ventures, CS Ventures, Bison Ventures and MBX Capital. “Vivodyne is fundamentally changing how drugs move from the lab bench to human trials.A model that is only predictive 5% of the time isn’t a model. We’re redefining success in drug discovery by overcoming the limitations that have stalled scientific progress for decades,” Andrei Georgescu, Vivodyne CEO and co-founder.